Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07700992 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring

Study acronym: PANXEON
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an asymptomatic early phase, late diagnosis, and poor survival, particularly in individuals who develop disease outside the context of early-stage detection. Early detection strategies are currently limited to imaging-based surveillance (MRI and endoscopic ultrasound) in selected high-risk populations, but these approaches are invasive, costly, and suboptimal in sensitivity. The aim of this study is to evaluate circulating cell-free and exosome-bound microRNAs as non-invasive biomarkers of PDAC risk and disease biology
Trial Details
NCT Number NCT07700992
Lead Sponsor Università Vita-Salute San Raffaele
Conditions
(from sponsor)		 Familial Pancreatic Cancer, Familial Pancreatic Carcinoma, Hereditary Pancreatic Cancer, Hereditary Pancreatitis, Pancreas Cancer, Pancreas Neoplasm, Pancreas Adenocarcinoma, Pancreas Cyst +2 more
Related terms Hereditary pancreatitis, Pancreatic carcinoma, familial, Pancreatic Cyst, Pancreatic Neoplasms
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov